摘要
AIM To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization(TACE) treatment for intermediate hepatocellular carcinoma(HCC).METHODS Sixty-seven patients with intermediate-stage [Barcelona Clinic liver cancer stage B(BCLC-B)] HCC who were treated with sorafenib plus TACE or TACE alone between 2009 and 2011 were included in the study. Follow-up was until 2014 or patient death. Two groups were defined in the experiment: The experimental group, treated with sorafenib plus TACE, and the control group, treated with standard TACE alone.RESULTS The Kaplan-Meier survival analysis showed that the median overall survival(m OS) of the experimental group was 35.2 mo, while that of the control group was 22.0 mo(P < 0.05). Sorafenib plus TACE showed higher incidence rates of rash, hand-foot syndrome(HFS), and hypertension(P < 0.05) than TACE treatment alone.CONCLUSION Sorafenib plus TACE treatment for BCLC-B HCC significantly prolonged the m OS of patients compared to TACE treatment alone. The most common toxicities with sorafenib were rash(31.6%), HFS(39.5%) and hypertension(31.6%), but there were no intolerable adverse events. The Cox multivariate analysis showed that the survival of patients with BCLC-B HCC depended on the Child-Pugh classification, tumor diameter, and treatment with sorafenib plus TACE compared to TACE alone.
AIM To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization(TACE) treatment for intermediate hepatocellular carcinoma(HCC).METHODS Sixty-seven patients with intermediate-stage [Barcelona Clinic liver cancer stage B(BCLC-B)] HCC who were treated with sorafenib plus TACE or TACE alone between 2009 and 2011 were included in the study. Follow-up was until 2014 or patient death. Two groups were defined in the experiment: The experimental group, treated with sorafenib plus TACE, and the control group, treated with standard TACE alone.RESULTS The Kaplan-Meier survival analysis showed that the median overall survival(m OS) of the experimental group was 35.2 mo, while that of the control group was 22.0 mo(P < 0.05). Sorafenib plus TACE showed higher incidence rates of rash, hand-foot syndrome(HFS), and hypertension(P < 0.05) than TACE treatment alone.CONCLUSION Sorafenib plus TACE treatment for BCLC-B HCC significantly prolonged the m OS of patients compared to TACE treatment alone. The most common toxicities with sorafenib were rash(31.6%), HFS(39.5%) and hypertension(31.6%), but there were no intolerable adverse events. The Cox multivariate analysis showed that the survival of patients with BCLC-B HCC depended on the Child-Pugh classification, tumor diameter, and treatment with sorafenib plus TACE compared to TACE alone.
基金
National Natural Science Foundation of China,No.81360360 and No.81660399
Yunnan Provincial Engineering Research Center of Major Surgical Diseases(2014)
Innovation Research Team Project of Yunnan Institutions of Higher Education(2014)
Innovation Research Team Project of Yunnan Province,No.2015HC033
Yunnan Provincial Academician Workstation of Xiaoping Chen(2016)
Breeding Program for Major Scientific and Technological Research Achievements of Kunming Medical University,No.CGPY201607
the Medical Leading Talent Project of Yunnan Province(to Wang L)
No.L201622
